Diabetes drug could shield heart muscle during angioplasty

NCT ID NCT06342141

Ongoing Disease control Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3 days. The study measures blood flow, heart strain, and infarct size. It is active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance)
What this could lead to: If it works, this could point toward a new way to prevent heart muscle damage during angioplasty for heart attacks.
What could go wrong: This is a small, early-phase trial (162 people) and the drug is already approved for diabetes, so the heart benefit is unproven. It may not reduce no-reflow or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NO-REFLOW PHENOMENON are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

No-Reflow Phenomenon ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NO-REFLOW PHENOMENON STEMI

Contacts and locations

Locations

National Institute of Cardiology

Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.